Bruker’s Expansion into Next-Generation Sequencing (NGS) Applications in Microbiology
During the ESCMID Global 2025 conference, Bruker, a leading provider of scientific instruments for molecular and materials research, made an exciting announcement. The Microbiology and Infection Diagnostics division of Bruker is broadening its microbiology solutions to encompass Next-Generation Sequencing (NGS) applications.
New Solutions for Epidemiology and Hospital Acquired Infection (HAI) Tracing
Bruker’s collaboration with Ridom GmbH, a German bioinformatics company, will facilitate the development of research-use only NGS-based solutions for epidemiology and hospital-acquired infection (HAI) tracing. These advanced tools aim to enhance the identification and understanding of microbial pathogens responsible for various infections, ultimately leading to improved patient care and public health.
Implications for Research and Clinical Settings
The integration of NGS technology into Bruker’s microbiology offerings will bring significant benefits to both research and clinical settings. In research environments, scientists will have access to more comprehensive and accurate data for studying the genetic makeup of microorganisms, enabling a deeper understanding of their mechanisms and evolution. This will lead to the development of new diagnostics, treatments, and preventive measures.
In clinical settings, the implementation of NGS-based solutions will enable faster and more precise identification of pathogens, allowing for more effective treatment and reducing the risk of antibiotic resistance. Moreover, these tools will support the early detection and tracking of HAIs, thereby minimizing the spread of infections in healthcare facilities.
Global Impact of NGS in Microbiology and Infectious Disease Testing
The expansion of Bruker’s microbiology solutions into NGS applications is a significant step towards improving the diagnosis and understanding of infectious diseases. This development will not only impact the healthcare industry but also influence various sectors such as food safety, water quality, and environmental monitoring.
The global market for NGS in microbiology and infectious disease testing is expected to grow substantially in the coming years, driven by the increasing demand for rapid, accurate, and cost-effective diagnostic tools. The integration of NGS technology into Bruker’s microbiology offerings will position the company at the forefront of this growing market and contribute to the advancement of scientific research and clinical care.
Conclusion
Bruker’s announcement of expanding its microbiology solutions into Next-Generation Sequencing (NGS) applications at the ESCMID Global 2025 conference is a significant development in the field of microbiology and infectious disease testing. The collaboration with Ridom GmbH will enable Bruker to offer research-use only NGS-based solutions for epidemiology and hospital-acquired infection (HAI) tracing. This integration of NGS technology will bring numerous benefits to both research and clinical settings, ultimately leading to improved patient care, public health, and scientific advancements.
The global impact of this development will be substantial, with the market for NGS in microbiology and infectious disease testing expected to grow significantly in the coming years. Bruker’s position at the forefront of this market will contribute to the advancement of scientific research and clinical care, making a difference in the lives of people around the world.
